- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
Détention brevets de la classe C07K 16/10
Brevets de cette classe: 5245
Historique des publications depuis 10 ans
|
245
|
225
|
256
|
266
|
279
|
422
|
529
|
511
|
463
|
224
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2871 |
145 |
| Humabs Biomed SA | 123 |
85 |
| Regeneron Pharmaceuticals, Inc. | 4335 |
82 |
| Vanderbilt University | 1917 |
79 |
| The Scripps Research Institute | 1348 |
75 |
| The Rockefeller University | 568 |
74 |
| Duke University | 3087 |
64 |
| VIR Biotechnology, Inc. | 146 |
58 |
| California Institute of Technology | 3986 |
47 |
| The Wistar Institute of Anatomy and Biology | 455 |
44 |
| Dana-Farber Cancer Institute, Inc. | 2593 |
41 |
| The Trustees of Columbia University in the City of New York | 3589 |
37 |
| Academia Sinica | 946 |
37 |
| Institut Pasteur | 782 |
37 |
| The Trustees of the University of Pennsylvania | 4342 |
36 |
| International AIDS Vaccine Initiative | 90 |
35 |
| Visterra, Inc. | 132 |
35 |
| The Regents of the University of California | 20087 |
30 |
| Genmab A/S | 428 |
30 |
| MedImmune Limited | 619 |
28 |
| Autres propriétaires | 4146 |